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Glutamate-mediated excitotoxicity induces neuronal death by altering various intracellular signaling pathways and is implicated as a
common pathogenic pathway in many neurodegenerative diseases. In the case of motor neuron disease, there is significant evidence to
suggest that the overactivationofAMPAreceptors due to deficiencies in the expression and functionof glial glutamate transportersGLT1
andGLASTplays an important role in themechanisms of neuronal death. However, a causal role for glial glutamate transporter dysfunc-
tion in motor neuron death remains unknown. Here, we developed a new animal model of excitotoxicity by conditionally deleting
astroglial glutamate transporters GLT1 and GLAST in the spinal cords of mice (GLAST//GLT1-cKO). GLAST//GLT1-cKO mice
(both sexes) exhibited nuclear irregularity and calpain-mediated degradation of nuclear pore complexes (NPCs), which are responsible
for nucleocytoplasmic transport. These abnormalities were associated with progressive motor neuron loss, severe paralysis, and short-
ened lifespan. The nuclear export inhibitor KPT-350 slowed but did not preventmotor neuron death, whereas long-term treatment of the
AMPAreceptor antagonist perampanel and the calpain inhibitor SNJ-1945 hadmore persistent beneficial effects. Thus,NPCdegradation
contributes to AMPA receptor-mediated excitotoxic motor neuronal death, and preventing NPC degradation has robust protective
effects. Normalization of NPC function could be a novel therapeutic strategy for neurodegenerative disorders in which AMPA receptor-
mediated excitotoxicity is a contributory factor.
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Introduction
Glutamate is a major excitatory neurotransmitter that regulates
virtually all activities of the CNS including motor control, learn-
ing and memory, and cognition. However, excess extracellular
glutamate can result in neuronal dysfunction anddeath, a process
known as excitotoxicity (Lucas andNewhouse, 1957; Olney et al.,
1974). Excess extracellular glutamate causes neuronal death by
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Significance Statement
Despite glial glutamate transporter dysfunction leading to excitotoxicity has been documented in many neurological diseases, it
remainsunclearwhether its dysfunction is a primary cause or secondary outcomeof neuronal death at disease state.Herewe show
the combined loss of glial glutamate transporters GLT1 and GLAST in spinal cord caused motor neuronal death and hindlimb
paralysis. Further, our novel mutant exhibits the nuclear irregularities and calpain-mediated progressive nuclear pore complex
degradation. Our study reveals that glial glutamate transporter dysfunction is sufficient to cause motor neuronal death in vivo.
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the disruption of intracellular organelles and aberrant proteolysis
via ion-sensitive protease activation that results from excessive
Ca2 influx following the overstimulation of Ca2-permeable glu-
tamate receptors (Hollmann et al., 1991;Verdoorn et al., 1991; Bano
et al., 2005; Kwak and Weiss, 2006; Lewerenz and Maher, 2015).
Accumulating evidence implicates excitotoxicity involvement in the
pathogenesis of many neurodegenerative diseases including Alzhei-
mer’s disease, multiple sclerosis, Parkinson’s disease, Huntington’s
disease, frontotemporal dementia (FTD), and amyotrophic lateral
sclerosis (ALS; Kawahara et al., 2004; Kwak andWeiss, 2006;Mehta
et al., 2013; Zhang et al., 2016), suggesting that these diseases may
share excitotoxicity as a commonpathogenicpathway.Thus, under-
standing themolecularmechanisms underlying chronic excitotoxic
neuronal death is of critical importance for the treatment of many
neurodegenerative diseases.
There may be a number of mechanisms by which excito-
toxicity is initiated: increased glutamate level due to enhanced
glutamate release; increased glutamate level due to glutamate
transporter dysfunction; and altered expression or sensitivity of
glutamate receptors. Glutamate transporter dysfunction iswidely
documented in many neurodegenerative diseases such as Alzhei-
mer’s disease and ALS (Fontana, 2015; Miladinovic et al., 2015).
There are five subtypes of Na-dependent glutamate transport-
ers, GLAST (EAAT1), GLT1 (EAAT2), EAAC1 (EAAT3), EAAT4,
and EAAT5. GLAST andGLT1 are mainly expressed in astrocytes,
while EAAT3, EAAT4, and EAAT5 are mainly expressed in neu-
rons (Tanaka, 2000). Astroglial glutamate transporters (GLAST
and GLT1) are the glutamate transporters mainly involved in the
maintenance of physiological extracellular glutamate concentra-
tions (Tanaka, 2005). In ALS, there is significant evidence to
suggest that the dysfunction of glial glutamate transporters plays
an important role in the pathogenic pathways of AMPA receptor-
mediated motor neuron death. ALS patients show reduced glu-
tamate uptake in the motor cortex and spinal cord (Rothstein et
al., 1990), which results from a reduction of the glial glutamate
transporter GLT1 (also known as EAAT2; Rothstein et al., 1995).
In addition, recent studies have reported that the spinal cord of
transgenic rats expressing mutant human TDP-43 selectively in
astrocytes exhibit a progressive deletion of GLAST, another glial
glutamate transporter, as well as GLT1 (Tong et al., 2013). How-
ever, it remains unknown whether the dysfunction of glial gluta-
mate transporters is a primary cause or a secondary consequence
of motor neuron degeneration. To explore a causal role for glial
glutamate transporter dysfunction in motor neuron death and
the signaling cascades leading to glutamate-mediated neuronal
death, we generated a novel mouse model of chronic glutamate
excitotoxicity by deletingGLT1 andGLAST from the spinal cord,
because mouse with a complete deficiency of GLT1 exhibited
seizure and premature death (Tanaka et al., 1997).
Materials andMethods
Mice. All animal procedures were performed in accordance with the
animal experiment plan approved by the Tokyo Medical and Dental
University Animal Care and Use Committee. Mice were housed three to
five animals per cage and were maintained on a regular 12 h light/dark
cycle (light period, 8:00 A.M. to 8:00 P.M.) at a constant 25°C. Food and
water were available ad libitum. In particular, when animals showed
complete hindlimb paralysis,moistened food andwater weremade easily
accessible to the animals on the cage floor. In the rare presence of a
moribund animal, the animal was killed. Animal experiments were
performed according to the Internal Institutional Review Committee.
Floxed-GLT1 mice, Hoxb8-Cre transgenic mice, and GLAST knock-out
(KO) mice were previously described (Watase et al., 1998; Witschi et al.,
2010; Cui et al., 2014; Aida et al., 2015). Both male and female mice were
used unless otherwise noted, and the number of male and female mice is
described in sample sizes by experiment. The age and number of mice
used for all experiments are described in the figure legends.
Behavioral tests. Behavioral analyses were performed by investigators
blind to the condition, genotype, and drug treatment groups.
Hanging wire test. Hanging wire tests were performed as previously
described (Hanada et al., 2013). Briefly, male mice were placed on a wire
netting, and the netting was turned over and held 50 cm above the table-
top for 60 s. The time until the hindlimbs disengaged from the wire
netting was recorded as the latency to fall.
Hindlimb reflex score. The posture of hindlimbs was scored as previ-
ously described (Wils et al., 2010). Briefly, malemice were tail suspended
for 14 s and scored using an established definition: 0, normal; 1, failure to
stretch their hindlimbs; 2, hindlimb clasping; 3, hindlimb paralysis.
Histology.Histological analysis was performed as previously described
(Cui et al., 2014; Aida et al., 2015). Mice deeply anesthetized with pento-
barbital (100 mg/kg, i.p.) were fixed by perfusion with 4% paraformal-
dehyde (PFA) in PBS. Brains and spinal cords were dissected and further
fixed with 4% PFA overnight. Tissues were transferred to 30% sucrose/
PBS for cryoprotection and separated into brain, cervical, thoracic, and
lumbar spinal cords in OCT compound (Sakura). Cryosections were
prepared at a 20m thickness for spinal cords and a 50m thickness for
brain (CM3050s, Leica) and mounted on MAS-coated slides (Matu-
nami). Cryosections were permeabilized and blocked with 0.3% Triton
X-100, 1% bovine serum albumin (BSA), and 10%normal goat serum in
PBS, and were incubated with primary antibodies overnight at 4°C. For
choline acetyltransferase (ChAT), sections were heated in 10 mM citrate
buffer, pH 6.0, at 100°C for 20min then were permeabilized and blocked
with 0.3% Triton X-100, 1% BSA, and 10% normal horse serum in PBS.
The following antibodies were used: polyclonal anti-GLT1 (1:5000; a gift
fromM.Watanabe,HokkaidoUniversity, Sapporo, Japan; Yamada et al.,
1998), polyclonal anti-ChAT (1:200; MAB144P,MerckMillipore), poly-
clonal anti-glial fibrillary acidic protein (GFAP; 1:1000; Z0334, Dako),
polyclonal anti-CD68 (1:100; MCA1957, AbD Serotec), monoclonal
anti-NeuN (1:500; MAB377, Millipore), monoclonal anti-Nup153 (1:
100; ab24700, Abcam), rabbit polyclonal anti-TDP-43 (1:100; 10782-
2AP, Proteintech), goat polyclonal anti-Lamin B1 (1:200; sc-6217, Santa
CruzBiotechnology),mousemonoclonal anti-KPNB1(1:200; sc-137016, Santa
Cruz Biotechnology), polyclonal anti-RanBP1 (1:500; NB100-79814,
Novus Biologicals), and polyclonal anti-cellular apoptosis susceptibility
(CAS; 1:100; ab96755, Abcam) antibodies. Sections were washed, incu-
batedwith secondary antibodies conjugatedwithAlexa Fluor 488, 594, or
633, and DAPI (Life Technologies) for 2 h, and mounted with Fluoro-
mount (Diagnostic BioSystems). For ChAT and Lamin B1 staining, sec-
tions were incubated with biotinylated donkey anti-goat IgG (1:200;
Vector Laboratories) for 2 h, washed, and incubated with streptavidin
conjugated with Alexa Fluor 488 (1:200; Invitrogen) for 2 h. For fluores-
cent Nissl staining, sections were incubated with NeuroTrace 640/660
Deep-Red Fluorescent Nissl Stain (1:100; Invitrogen) for 30 min, im-
mersed in 0.3% Triton-X in PBS for 15 min, and washed two times in
PBS. For GLT1 staining, sections were incubated with biotinylated goat
anti-rabbit IgG (1:1000; Vector Laboratories) for 1 h, immersed in 1%
H2O2/PBS, and incubatedwith AB complex (1:500; Vector Laboratories)
for 1 h, and then visualized with a DAB substrate kit (Vector Laborato-
ries). Images were acquired using an LSM710 Laser Scanning Confocal
Microscope (Carl Zeiss) or an SZX16 StereoscopicMicroscope for GLT1
immunostaining (Olympus).
Electron microscopy. Mice deeply anesthetized with pentobarbital
(100 mg/kg, i.p.) were fixed by perfusion with 4% PFA and 2.5% glutar-
aldehyde in 0.1 M phosphate buffer, pH 7.4. Spinal cords were dissected
and further fixed with same fixative overnight. After dehydration, sam-
ples were embedded in Epon 812. Ultrathin sections were stained with
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2%uranyl acetate for 20min and lead citrate solution for 5min. Electron
micrographs were taken on an H7100 electron microscope (Hitachi).
Cell counts.Cell countswere performedusing ImageJ softwarewith the
cell counter plug-in (National Institutes of Health, Bethesda, MD) by
investigators who were blind to genotype and drug treatment. Formotor
neurons, the number of ChAT-positive cells in the bilateral ventral horns
of L3–L5 in three to nine serial sections was counted. For the other
neurons, NeuN-positive cells in laminae I–IV were counted. Laminae
boundaries were determined according to cytoarchitectonic criteria pre-
viously described (Wootz et al., 2013). For glial cells, GFAP- and CD68-
positive cells in bilateral ventral horns of L3–L5 in three serial sections
were counted. Motor neurons showing nuclear irregularity were defined
as motor neurons (large ventral horn neurons with a nuclear diameter of
10 m) in which laminB1-immunolabeled nuclear contour showed
discontinuous and frayed morphology, such as a ruffled edge and pedal-
like shape (Freibaum et al., 2015). Nup153-negativemotor neurons were
defined as motor neurons (large ventral horn neurons with a nuclear
diameterof10m) inwhichmore thanhalf ofNup153-immunolabelednu-
clear contours were lost. Motor neurons showing TDP-43 pathology
were defined as ChAT-positive cells displaying aberrant staining patterns
of TDP-43, such as mislocalization to the cytoplasm (mislocalization),
nuclear reduction without cytoplasmic immunoreactivity (reduction),
and absence from both the nucleus and the cytoplasm (absence). CAS-
negative motor neurons were defined as ChAT-positive cells in which
more than half of CAS immunoreactivity was lost from the nucleus.
Western blot analysis. Western blot analysis was performed as previ-
ously described (Aida et al., 2015). Brains and spinal cords were dissected
after perfusion with ice-cold PBS. Brain hemisphere or lumbar spinal
cords were homogenized in 0.32 M sucrose, 20 mM Tris-HCl, pH 7.5,
1mMNaVO4, 1mMNaF, and a protease inhibitor cocktail (Roche). After
the calculation of protein concentrations by BCA assay (Sigma-Aldrich),
samplesweremixedwithanequal amountof sample loadingbuffer (250mM
Tris-HCl, pH 6.8, 4% SDS, 10% glycerol, and 1% -mercaptoethanol) and
denatured by heating at 95°C for 10 min. Thirty micrograms of each
sample was separated by 10% SDS-PAGE, transferred to PVDF mem-
branes (Merck Millipore), and blocked in Tris-buffered saline (TBS)
with 0.5% Tween 20 (TBS-T) and 5% skimmilk for 1 h at room temper-
ature. Themembranes were incubatedwith primary antibodies in TBS-T
containing 1% skim milk at 4°C overnight, washed, and incubated with
horseradish peroxidase (HRP)-conjugated secondary antibodies at room
temperature for 1 h. The following antibodies were used: polyclonal
anti-GLAST (1:1000; a gift from M. Watanabe, Hokkaido University),
polyclonal anti-GLT1 (1:5000; a gift fromM.Watanabe, Hokkaido Uni-
versity), polyclonal anti-EAAC1 (1:500; sc-25658, Santa Cruz Biotech-
nology), monoclonal anti-Nup62 (1:500; BD Biosciences), monoclonal
anti-Nup153 (1:500; Abcam), polyclonal anti-Nup88 (1:1000; ab79785,
Abcam), goat polyclonal anti-Lamin B1 (1:2000; sc-6217, Santa Cruz
Biotechnology), monoclonal anti-spectrin (1:5000; MAB1622, Milli-
pore), rabbit polyclonal anti-p35 (1:250; sc-820, Santa Cruz Biotechnol-
ogy), rabbit polyclonal anti-TDP-43 (1:2000; 10782-2AP, Proteintech),
monoclonal anti--tubulin (1:5000; T7451; Sigma-Aldrich), monoclo-
nal anti--actin (1:5000; sc-47778, Santa Cruz Biotechnology), and
HRP-conjugated anti-rabbit ormouse IgG (1:5000; Jackson ImmunoRe-
search) antibodies. The membranes were washed and visualized with
Luminata Forte Western HRP substrate (Millipore). Gel images were
taken and quantified by measuring the ratio of the band intensities nor-
malized to the intensity of-actin or-tubulin using Image Lab Software
(Bio-Rad).
In vitro calpain activity analysis. In vitro calpain activity analysis was
previously described (Sato et al., 2011). The mouse brains were homog-
enized in 10 volumes (volume/weight) of HEPES buffer (20 mMHEPES,
pH 7.5, 5mMKCl, 2mMMgCl2, 1mM EGTA, and 1mM dithiothreitol) at
4°C using a Teflon pestle in a glass homogenizer. The homogenates were
centrifuged at 18,000 g for 20min, and the resulting supernatants were
collected. The supernatant was incubated in vitro with exogenous
5 mM CaCl2 at 30°C. Proteolysis of Nup153, Nup88, Nup62, LaminB1,
-spectrin, and TDP-43 was assessed by immunoblotting, as described
above.
Measurement of endogenous calpain activity. Calpain activity was mea-
sured using a kit from BioVision following manufacturer instructions.
Briefly, tissue lysates were prepared from lumbar ventral horn of each
mouse in extraction buffer and the homogenates were centrifuged at
13,200 rpm for 5 min at 4°C. After collecting supernatant, protein
concentration was determined by BCA assay (Sigma-Aldrich). Fifty mi-
crograms of protein was used for the calpain assay, as described by the
manufacturer. Fluorescence emitted from calpain substrates and a cleaved
one was quantified using a fluorescence microplate reader equipped with a
400 nm excitation filter, a 505 nm emission filter (Spark 10M, Tecan). Cal-
pain activitywas calculated as relative fluorescence units using Spark Con-
trol Software (Tecan).
Drug treatment. Perampanel (Hanada et al., 2011) provided by Eisai
was dissolved in 0.5% (w/v)methylcellulose (Wako Pure Chemicals) and
orally administered to themice at a dose of 20mg/kg once a day from6 to
7 weeks of age. Memantine (Sigma-Aldrich) dissolved in saline was in-
jected intraperitoneally into the mice at a dose of 10 mg/kg twice a day
from6 to 7weeks of age.MK-801 (Sigma-Aldrich) dissolved in salinewas
injected intraperitoneally into the mice at a dose of 3 mg/kg once a day
from 6 to 8 weeks of age. SNJ-1945 (Oka et al., 2006) provided by Senju
Pharmaceutical Co. was dissolved in 0.5% (w/v) sodium carboxymethyl
cellulose (Wako Pure Chemicals) and orally administered to the mice at
a dose of 200mg/kg once a day from6 to 7weeks of age. KPT-350 (Haines
et al., 2015) provided by Karyopharm Therapeutics was dissolved 0.6%
Pluronic F-68 (w/v) and 0.6% PVP K-29/32 (w/v) in water and orally
administered to the mice at a dose of 15 mg/kg every other day from 6 to
7 weeks of age. The hanging wire test was performed 24 h after the final
administration, and then themice were fixed by perfusion with 4% PFA/
PBS and subjected to quantification of motor neurons.
To examine the long-term effects of perampanel and SNJ-1945, mice
were treated daily with perampanel (20 mg/kg, orally) or SNJ-1945
(200 mg/kg, orally) for 42 d starting at 6 weeks of age. Since a 15 mg/kg
dose of KPT-350 is not a safe dose for long-term treatment, we orally
administered KPT-350 (7.5 mg/kg) three times per week from 6 to 12
weeks of age (Haines et al., 2015). Drug-treated and vehicle-treated ani-
mals were monitored daily for survival and weekly for grip strength. In
the hanging wire test, we replaced the missing values in the latency to fall
with 0 s when mice died during the long-term treatment.
Mice were fixed 24 h after the final administration by perfusion with
4% PFA/PBS and subjected to the quantification of motor neurons.
Experimental design. All experiments were performed with appropri-
ate controls such as GLT1 flox/flox mice and vehicle-treated GLAST//
GLT1-cKO mice. The type, number, and sexes of the animals used for
each experiment are detailed in the figures as follows:
Figure 1C–F: 3 GLT1 flox/flox (control, 3 females), 3 Hoxb8-Cre/
GLT1 flox/flox (3 females), 3 GLAST//GLT1 flox/flox (3 females), and
3 Hoxb8-Cre/GLT1 flox/flox/GLAST/ (GLAST//GLT1-cKO, 3 fe-
males) mice.
Figure 1G–I: 15 control (15 males) and 16 GLAST//GLT1-cKO
(16 males) mice.
Figure 1J: 11 control (11 males) and 14 GLAST//GLT1-cKO
(14 males) mice.
Figure 2B: P5W, 4 control (4 males) and 5 GLAST//GLT1-cKO (5
males) mice; P6W, 4 control (4 males) and 4 GLAST//GLT1-cKO (4
males) mice; P7W, 3 control (3 males) and 4 GLAST//GLT1-cKO
(4 males) mice; P8W, 3 control (3 males) and 3 GLAST//GLT1-cKO (3
males) mice; P9W, 4 control (4 males) and 5 GLAST//GLT1-cKO (5
males) mice; and P20W, 3 control (1 male, 2 females) and 4 GLAST//
GLT1-cKO (1male, 3 females) mice.
Figure 2D: P5W, 3 control (2 males, 1 female) and 3 GLAST//
GLT1-cKO (2 males, 1 female) mice; P7W, 4 control (4 males) and 4
GLAST//GLT1-cKO (4 males) mice; P9W, 3 control (3 males) and 4
GLAST//GLT1-cKO (4 males) mice; and P20W, 3 control (1 male, 2
female) and 3 GLAST//GLT1-cKO (1 male, 2 female) mice.
Figure 2F,H: P5W, 3 control (2 males, 1 female) and 3 GLAST//
GLT1-cKO (2 males, 1 female) mice; P6W, 3 control (2 males, 1 female)
and 3 GLAST//GLT1-cKO (2 males, 1 female) mice; P7W, 4 control
(4 males) and 4 GLAST//GLT1-cKO (4male) mice; P8W 3 control (2
males, 1 female) and 3GLAST//GLT1-cKO (3males); P9W, 3 control
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(3 males) and 3 GLAST//GLT1-cKO (3 males) mice; and P20W, 3
control (1 male, 2 females) and 3 GLAST//GLT1-cKO (1 male, 2
females) mice.
Figure 3A: 15 vehicle-treated GLAST//GLT1-cKO (15 males) and
17 perampanel-treated GLAST//GLT1-cKO (17 males) mice.
Figure 3D: 3 control (3 males), 4 vehicle-treated GLAST//GLT1-
cKO (4 males) and 5 perampanel-treated GLAST//GLT1-cKO (5
males) mice.
Figure 3E: 9 vehicle-treated GLAST//GLT1-cKO (5 males, 4 fe-
males) and 7 memantine-treated GLAST//GLT1-cKO (4 males, 3 fe-
males) mice.
Figure 3G: 3 vehicle-treated GLAST//GLT1-cKO (3 females) and 4
memantine-treated GLAST//GLT1-cKO (1 male, 3 female) mice.
Figure 3H: 5 vehicle-treated GLAST//GLT1-cKO (4 males, 1 fe-
males) and 6 MK-801-treated GLAST//GLT1-cKO (4 males, 2 fe-
male) mice.
Figure 3J: 3 vehicle-treated GLAST//GLT1-cKO (3 males) and 3
MK-801-treated GLAST//GLT1-cKO (2 male, 1 female) mice.
Figure 4C: P4W, 3 control (3 females) and 3GLAST//GLT1-cKO (3
females) mice; P5W, 3 control (1 male, 2 females) and 4 GLAST//
GLT1-cKO (2 males, 2 females) mice; P6W, 4 control (4 males) and 6
GLAST//GLT1-cKO (3 males, 3 females) mice; P7W, 5 control (5
males) and 4 GLAST//GLT1-cKO (2 males, 2 females) mice; P8W, 3
control (3 females) and 3 GLAST//GLT1-cKO (2 male, 1 females)
mice; and P9W, 3 control (2 males, 1 female) and 3 GLAST//GLT1-
cKO (2 males, 1 female) mice.
Figure 4E: P4W, 3 control (3 females) and 3GLAST//GLT1-cKO (3
females) mice; P5W, 3 control (1 male, 2 females) and 4 GLAST//
GLT1-cKO (2males, 2 females) mice; P6W, 3 control (1male, 2 females)
and 3 GLAST//GLT1-cKO (1 male, 2 females) mice; and P7W, 3
control (3 males) and 4 GLAST//GLT1-cKO (4 males) mice.
Figure 4G: 4 control (3 males, 1 female) and 5 GLAST//GLT1-cKO
(4 males, 1 female) mice.
Figure 5C: P5W, 3 control (1 male, 2 females) and 3 GLAST//
GLT1-cKO (1make, 2 females)mice; and P6W, 4 control (4 females) and
3 GLAST//GLT1-cKO (3 females) mice.
Figure 1. Conditional knockout of astroglial glutamate transporters in the spinal cord causes paralysis and motor neuron death. A, Schematic diagram showing the generation of GLAST//
GLT1-cKO mice. B, GLT1 immunohistochemistry in brain, cervival (C6), thoracic (T2 and T10), and lumbar (L5) spinal cord tissue at 3 months of age. Scale bars: top, 5 mm; bottom, 500 m.
C,D, Western blot analysis of GLT1 in the brains (C) and lumbar spinal cords (D) of control (GLT1 flox/flox), Hoxb8-Cre/GLT1 flox/flox, GLAST//GLT1 flox/flox, and Hoxb8-Cre/GLT1 flox/flox /GLAST/
(GLAST//GLT1-cKO)mice at 4weeks of age (n 3 for each groups). GLT1monomer band intensitieswere normalized to-actin. **p 0.01. n.s., not significant ( post hoc Tukey-HSD test after
one-way ANOVA). E, Western blot analysis of GLAST in the lumbar spinal cord of control, Hoxb8-Cre/GLT1 flox/flox, GLAST//GLT1 flox/flox, and GLAST//GLT1-cKOmice at 4 weeks of age (n
3 for each groups). GLAST band intensities were normalized to-actin. **p 0.01 ( post hoc Tukey HSD test after one-way ANOVA). F, Western blot analysis of EAAC1 in the lumbar spinal cord of
control, Hoxb8-Cre/GLT1 flox/flox, GLAST//GLT1 flox/flox, and GLAST//GLT1-cKOmice at 4 weeks of age (n 3 for each groups). EAAC1 band intensities were normalized to-actin. n.s., not
significant (one-way ANOVA).G–I, Body weight changes (G), hindlimb reflex score (H ), and hangingwire test (I ) of control (GLT1 flox/flox, n 15) and GLAST//GLT1-cKO animals (Hoxb8-Cre/
GLT1 flox/flox /GLAST/, n 16). ***p 0.001 ( post hoc unpaired two-tailed t test at corresponding time-point after two-way repeated-measures ANOVA). J, Percentage survival of control
(n 11) and GLAST//GLT1-cKO (n 14) animals calculated using the Kaplan–Meier method ( p 0.000016, log rank test). All data are expressed as the mean SEM.
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Figure 2. Loss of motor neurons and gliosis in GLAST//GLT1-cKOmice. A, ChAT immunofluorescence of the lumbar ventral horn in control and GLAST//GLT1-cKOmice at 5, 7, 9, and 20
weeks of age. Scale bar, 50m.B, Quantification of ChAT-positivemotor neurons from5 to 9, and 20weeks of age of controlmice (P5W, n 4; P6W, n 4; P7W, n 3; P8W, n 3; P9W, n 4;
P20W,n3) andGLAST//GLT1-cKOmice (P5W,n5; P6W,n4; P7W,n4; P8W,n3; P9W,n5; P20W,n4). *p0.05, **p0.05, ***p0.001. n.s., not significant (unpaired
two-tailed t test). C, NeuN immunofluorescence in the lumbar dorsal horn from control and GLAST//GLT1-cKO mice at 20 weeks of age. Scale bar, 200m. D, Quantification of NeuN-positive
neurons in the superficial dorsal horn (laminae I–IV) of the spinal cord at 5, 7, 9, and 20weeks of controlmice (P5W, n 3; P7W, n 4; P9W, n 3; P20W, n 3) and GLAST//GLT1-cKOmice
(P5W, n 3; P7W, n 4; P9W, n 4; P20W, n 3) mice. E, GFAP immunofluorescence in the lumbar ventral horn from control and GLAST//GLT1-cKO mice at 5, 7, 9, and 20 weeks
of age. Scale bar, 100 m. F, Quantification of GFAP-positive cells in the lumbar ventral horn from 5 to 9, and 20 weeks of age of control mice (Figure legend continues.)
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Figure 5D: P4W, 5 control (2 males, 3 females) and 6 GLAST//
GLT1-cKO (2males, 4 females)mice; P5W, 6 control (3males, 3 females)
and 5 GLAST//GLT1-cKO (3 males, 2 females) mice; and P6W, 5
control (3 males, 2 females) and 6 GLAST//GLT1-cKO (3 males, 3
females) mice.
Figure 5F: P5W, 7 control (7 males) and 7 GLAST//GLT1-cKO (7
males) mice; P6W, 6 control (6 males) and 5 GLAST//GLT1-cKO (3
males, 2 females) mice; P7W, 5 control (5 males) and 6 GLAST//
GLT1-cKO (2 males, 4 females) mice; and P9W, 6 control (6 males) and
5 GLAST//GLT1-cKO (5 males) mice.
Figure 5H: 8 vehicle-treated GLAST//GLT1-cKO (6 males, 2 fe-
males) and 8 SNJ-1945-treated GLAST//GLT1-cKO (7 males, 1 fe-
males) mice.
Figure 5J: 5 vehicle-treated GLAST//GLT1-cKO (5 males) and 6
SNJ-1945-treated GLAST//GLT1-cKO (6 males) mice.
Figure 5L: 4 vehicle-treated GLAST//GLT1-cKO (4 males) and 4
SNJ-1945-treated GLAST//GLT1-cKO (4 males) mice.
Figure 5N: 4 vehicle-treated GLAST//GLT1-cKO (4 males) and 5
perampanel-treated GLAST//GLT1-cKO (5 males) mice.
Figure 6C: 3 control (3 males) and 4 GLAST//GLT1-cKO (3males,
1 female) mice.
Figure 6D: 10 vehicle-treated GLAST//GLT1-cKO (5 males, 5 fe-
males) and 9 KPT-350-treated GLAST//GLT1-cKO (3 males, 6 fe-
males) mice.
Figure 6G: 7 vehicle-treated GLAST//GLT1-cKO (2 males, 5 fe-
males) and 5 KPT-350-treated GLAST//GLT1-cKO (1 male, 4 fe-
males) mice.
Figure 6I: 3 vehicle-treatedGLAST//GLT1-cKO (1male, 2 females)
and 3 KPT-350-treated GLAST//GLT1-cKO (3 females) mice.
Figure 7A,B: 20 vehicle-treated GLAST//GLT1-cKO (11 males, 9
females) and 16 perampanel-treated GLAST//GLT1-cKO (8 males, 8
females) mice.
Figure 7D: 4 vehicle-treated GLAST//GLT1-cKO (3 males, 1 fe-
males) and 6 perampanel-treated GLAST//GLT1-cKO (3 males, 3
females) mice.
Figure 7E,F: 18 vehicle-treated GLAST//GLT1-cKO (9 males, 9
females) and 16 SNJ-1945-treated GLAST//GLT1-cKO (6 males, 10
females) mice.
Figure 7H: 4 vehicle-treated GLAST//GLT1-cKO (3 males, 1 fe-
male) and 6 SNJ-1945-treated GLAST//GLT1-cKO (2 males, 4 fe-
males) mice.
Figure 7 I, J: 19 vehicle-treated GLAST//GLT1-cKO (9 males, 10
females) and 14 KPT-350-treated GLAST//GLT1-cKO (7 males, 7
females) mice.
Figure 7L: 4 vehicle-treated GLAST//GLT1-cKO (2 males, 2 fe-
males) and 6 KPT-350-treated GLAST//GLT1-cKO (4 males, 2 fe-
males) mice.
Statistical analysis. All data are expressed as the mean  SEM. An
unpaired two-tailed t test was used to compare differences between any
two groups. One-way ANOVA with post hoc Tukey’s HSD test was used
to compare differences between among than three groups. For longitu-
dinal observations, two-way repeated-measures ANOVA with post hoc
unpaired two-tailed t test at the corresponding time point was per-
4
(Figure legend continued.) (P5W, n 3; P6W, n 3; P7W, n 4; P8W, n 3; P9W, n 3;
P20W, n 3) and GLAST//GLT1-cKO mice (P5W, n 3; P6W, n 3; P7W, n 4; P8W,
n 3; P9W, n 3; P20W, n 3) mice. *p 0.05, **p 0.01, ***p 0.001. G, CD68
immunofluorescence in the lumbar ventral horns from control and GLAST//GLT1-cKOmice
at 5, 7, 9, and 20weeks of age. Scale bar, 100m.H, Quantification of CD68-positive cells in the
lumbar ventral horn from5 to 9, and 20weeks of age of controlmice (P5W, n 3; P6W, n 3;
P7W, n 4; P8W, n 3; P9W, n 3; P20W, n 3) and GLAST//GLT1-cKO mice (P5W,
n 3; P6W, n 3; P7W, n 4; P8W, n 3; P9W, n 3; P20W, n 3). *p 0.05. All data
are expressed as the mean SEM. n.s., Not significant (unpaired two-tailed t test).
Figure 3. Overactivation of AMPA receptor but not NMDA receptor contributes to motor deficits and motor neuron loss in GLAST//GLT1-cKOmice. A, Perampanel treatment delayed motor
deficits in the hangingwire test (n 15 for vehicle-treated and n 17 for perampanel-treated GLAST//GLT1-cKOmice). *p 0.05 ( post hoc unpaired two-tailed t test at corresponding time
point after two-way repeated-measures ANOVA). B, Amelioration of hindlimb paralysis in GLAST//GLT1-cKOmice after perampanel treatment. Arrow indicates the fully paralyzed hindlimb of
vehicle-treated GLAST//GLT1-cKO mice. Arrowhead indicates the hindlimb upon which the perampanel-treated GLAST//GLT1-cKO mice could stand. C, ChAT immunofluorescence of the
lumbar ventral horn from control, vehicle-treated, and perampanel-treated GLAST//GLT1-cKOmice at 7 weeks of age. Scale bar, 100m. D, Quantification of ChAT-positive motor neurons at
7 weeks of age (n 3 for control mice, n 4 for vehicle-treated mice, and n 5 for perampanel-treated GLAST//GLT1-cKO mice). *p 0.05, ***p 0.001 ( post hoc Tukey HSD test after
one-way ANOVA). E, Memantine treatment could not amelioratemotor deficits in the hangingwire test (n 9 for vehicle-treated and n 7 for memantine-treated GLAST//GLT1-cKOmice).
n.s., Not significant (two-way repeated-measures ANOVA). F, ChAT immunofluorescence of the lumbar ventral horn from vehicle-treated andmemantine-treated GLAST//GLT1-cKOmice at 7
weeks of age. Scale bar, 100m.G, Quantification of ChAT-positivemotor neurons at 7weeks of age (n 3 for vehicle-treated and 4 formemantine-treated GLAST//GLT1-cKOmice). n.s., Not
significant (unpaired two-tailed t test).H,MK-801 treatment could not amelioratemotor deficits in the hangingwire test (n 5 for vehicle-treated and 6 forMK-801-treatedGLAST//GLT1-cKO
mice). n.s., Not significant (two-way repeated-measures ANOVA). I ChAT immunofluorescence of the lumbar ventral horn from vehicle-treated andMK-801-treated GLAST//GLT1-cKOmice at
8weeks of age. Scale bar, 100m. J, Quantification of ChAT-positivemotor neurons at 8weeks of age (n3 for each groups). n.s., Not significant (unpaired two-tailed t test). All data are expressed
as the mean SEM.
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formed. Significant differences were analyzed by Kaplan-Meier and log
rank tests for the survival rate. All statistical analyses were performed
using SPSS 24 (IBM). A p value of0.05was considered to be statistically
significant.
Results
Generation of spinal cord-specific astroglial glutamate
transporters KOmice (GLAST//GLT1-cKO)
Because astroglial glutamate transporters (GLT1 andGLAST) are
critical for the maintenance of extracellular glutamate and the
prevention of chronic excitotoxicity (Tanaka et al., 1997; Watase
et al., 1998; Matsugami et al., 2006), we generated mice that
lacked GLT1 specifically in the spinal cord on a GLAST hetero-
zygous background (Hoxb8-Cre/GLT1flox/flox/GLAST/ mice,
hereafter, denoted as “GLAST//GLT1-cKO mice”; Fig. 1A;
Watase et al., 1998;Witschi et al., 2010; Cui et al., 2014; Aida et al.,
2015). Immunohistochemistry and Western blot analysis of
GLT1 showed that the amount of GLT1 protein was gradually
reduced from the spinal cord caudal to the cervical level C6 and
completely lost in the lumbar spinal cord in GLAST//GLT1-
cKO mice, which was consistent with the pattern of Cre-
recombinase expression in the Hoxb8-Cre line [Fig. 1B–D; (Fig.
1C: one-way ANOVA, F(3,8)  0.11, p  0.95; Fig. 1D: one-way
Figure 4. Nuclear contour irregularity and the loss of nuclear pore complex proteins are observed in spinal motor neurons of GLAST//GLT1-cKOmice. A, Pseudocolored electronmicroscopic
images of motor neurons in lumbar ventral horns from control and GLAST//GLT1-cKOmice at 6 weeks of age. The nucleus of the motor neuron is pseudocolored in light blue. Scale bar, 2m.
B, Lamin B1 immunofluorescence of lumbar ventral horns from control and GLAST//GLT1-cKOmice at 7weeks of age. Sectionswere double labeledwith anti-lamin B1 (green) and DAPI (blue).
Rectangles inmiddle panel are enlarged in the right panel. Scale bars: left, 10m; right, 5m. C, Quantitative analysis of Lamin B1-immunostained sections. The percentage of large ventral horn
neurons showingnuclear contour irregularity is higher inGLAST//GLT1-cKOmice from5weeksof age. Largeventral hornneurons showingnuclear contour irregularitywere counted fromcontrol
mice (P4W, n 3; P5W, n 3; P6W, n 4; P7W, n 5; P8W, n 3; P9W, n 3) and GLAST//GLT1-cKOmice (P4W, n 3; P5W, n 4; P6W, n 6; P7W, n 4; P8W, n 3; P9W, n
3). *p 0.05, **p 0.01, ***p 0.001. n.s., Not significant (unpaired two-tailed t test). D, Nup153 immunofluorescence of lumbar ventral horns from control and GLAST//GLT1-cKO mice
at 6weeks of age. Sections were triple labeledwith anti-Nup153 (magenta), DAPI (blue), and Neurotrace (fluorescent Nissl stain, white). Rectangles in themiddle panel are enlarged in right panel.
Scale bars: left, 10m; right, 5m. E, Quantitative analysis of Nup153-immunostained sections. The percentage of Nup153-negative large ventral horn neurons is higher in GLAST//GLT1-cKO
mice from 6weeks of age. Nup153-negative large ventral horn neurons were counted from control mice (n 3 at each age), and GLAST//GLT1-cKOmice (P4W, n 3; P5W, n 4; P6W, n
3; P7W,n4)mice. *p0.05, ***p0.001. n.s., Not significant (unpaired two-tailed t test). All data are expressed as themean SEM.F, Nup153 immunofluorescence of lumbar ChAT-positive
motor neurons from control and GLAST//GLT1-cKOmice at 7weeks of age. Sectionswere triple-labeledwith anti-Nup153 (magenta), DAPI (blue), and ChAT (white). Rectangles inmiddle panel
are enlarged in right panel. Scale bars: left, 10m; right, 5m.G, Quantitative analysis ofNup153()/ChAT()motor neurons. ThepercentageofNup153 ()/ ChAT()motor neurons is similar
to that of Nup153() large ventral horn neurons in GLAST//GLT1-cKOmice at 7weeks of age (n 4 for control and n 5 for GLAST//GLT1-cKO). **p 0.01 (unpaired two-tailed t test).
All data are expressed as the mean SEM.
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ANOVA, F(3,8) 17.53, p 0.00071; post hoc Tukey HSD tests,
GLT1flox/flox vs Hoxb8-Cre/GLT1flox/flox, p  0.0039; GLT1flox/flox vs
GLAST//GLT1flox/flox, p 1.00;GLT1flox/flox vsGLAST//GLT1-
cKO,p0.0044;Hoxb8-Cre/GLT1flox/flox vsGLAST//GLT1flox/flox,
p 0.0036; Hoxb8-Cre/GLT1flox/flox vs GLAST//GLT1-cKO, p 
1.00; GLAST//GLT1flox/flox vs GLAST//GLT1-cKO, p 
0.0041)]. Western blot analysis of GLAST revealed an	50% re-
duction in the spinal cords of GLAST//GLT1flox/flox and
GLAST//GLT1-cKO mice when compared with GLT1flox/flox
(hereafter denoted as “control”) and Hoxb8-Cre/GLT1flox/flox
Figure 5. Calpain overactivation contributes to motor deficits and motor neuron loss in GLAST//GLT1-cKO mice. A, Representative immunoblot that shows proteolysis of Nup153, Nup88,
Nup62, laminB1, and-spectrin in mouse brain homogenate that was incubated with exogenous calcium and/or a calpain inhibitor, SNJ-1945 (100M). B, Representative immunoblot showing
proteolysis of p35 in lumbar ventral horn from control and GLAST//GLT1-cKOmice at 5 and 6 weeks of age. C, Quantification of the p25/p35 ratio from control mice (P5W, n 3; P6W, n 4)
and GLAST//GLT1-cKOmice (n 3 at each age). Band intensities of p35 and p25were normalized to-tubulin. **p 0.01. n.s., Not significant (unpaired two-tailed t test).D, Measurement
of calpain activity of lumbar ventral horn form control mice (P4W, n 5; P5W, n 6; P6W, n 5) and GLAST//GLT1-cKOmice (P4W, n 6; P5W, n 5; P6W, n 6). Relative fluorescence
units (RFUs) were compared by calculating the fold difference in enzyme activity. *p 0.05; n.s., Not significant (unpaired two-tailed t test). E, TDP-43 immunofluorescence in the lumbar ventral
horns fromcontrol at 7weeks of age (the top rowof a panel) andGLAST//GLT1-cKOmice at 7 (the second and third rows of a panel) and9 (the bottom rowof a panel)weeks of age. Sectionswere
double labeled with TDP-43 (red) and ChAT (white). Nuclei were visualized with DAPI. The second row of a panel shows mislocalization of TDP-43 to the cytoplasm in motor neurons of
GLAST//GLT1-cKOmice. The third rowof a panel shows reduction of nuclear TDP-43without cytoplasmic TDP-43 immunoreactivity inmotor neurons of GLAST//GLT1-cKOmice. The bottom
row of a panel shows loss of TDP-43 from both the nucleus (yellow arrowhead) and the cytoplasm in motor neurons of GLAST//GLT1-cKO mice. Scale bar, 10m. F, The percentage of motor
neurons showing aberrant staining pattern of TDP-43 from 5, 6, 7, and 9 weeks of age of control mice (P5W, n 7; P6W, n 6; P7W, n 5; P9W, n 6) and GLAST//GLT1-cKOmice (P5W,
n 7; P6W, n 5; P7W, n 6; P9W, n 5). *p 0.05, **p 0.01 (unpaired two-tailed t test). G, Representative immunoblot that shows proteolysis of TDP-43 and-actin in mouse brain
homogenate that was incubated with exogenous calcium and/or a calpain inhibitor, SNJ-1945 (100 M). Black and white arrowheads indicate a full-length and cleaved fragment of TDP-43,
respectively. H, SNJ-1945 treatment delayed motor deficits in the hanging wire test (n 8 for each groups). *p 0.05 ( post hoc unpaired two-tailed t test at corresponding time point after
two-way repeated-measures ANOVA). I, ChAT immunofluorescence of the lumbar ventral horns from vehicle-treated and SNJ-1945-treated GLAST//GLT1-cKOmice at 7weeks of age. Scale bar,
100 m. J, Quantification of ChAT-positive motor neurons at 7 weeks of age (n 5 for vehicle-treated and n 6 for SNJ-1945-treated GLAST//GLT1-cKO mice). **p 0.01 (unpaired
two-tailed t test). K, Nup153 immunofluorescence of lumbar ventral horns from vehicle-treated and SNJ-1945-treated GLAST//GLT1-cKO mice at 7 weeks of age. Sections were triple labeled
with anti-Nup153 (magenta), DAPI (blue), and Neurotrace (fluorescent Nissl stain, white). Rectangles in the middle panel are enlarged in the right panel. Scale bars: left, 10m; right, 5m.
L, Quantitative analysis of Nup153-immunostained sections. The percentage of Nup153-negative large ventral horn neurons decreased in GLAST//GLT1-cKOmice treatedwith SNJ-1945 (n 4 for each
groups).**p0.01(unpairedtwo-tailed t test).M,Nup153 immunofluorescenceof lumbarventralhorns fromvehicle-treatedandperampanel-treatedGLAST//GLT1-cKOmiceat7weeksofage.Sections
were triple labeledwithanti-Nup153(magenta),DAPI (blue), andNeurotrace (fluorescentNissl stain,white).Rectangles in themiddlepanelareenlarged in the rightpanel. Scalebars: left, 20m;right, 5m.
N, Quantitative analysis of Nup153-immunostained sections. The percentage of Nup153-negative large ventral horn neurons decreased in GLAST//GLT1-cKO mice treated with perampanel (n 4 for
vehicle-treated andn 5 for perampanel-treatedGLAST//GLT1-cKOmice). *p 0.05 (unpaired two-tailed t test). All data are expressed as themean SEM.
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mice (Fig. 1E [one-way ANOVA, F(3,8) 22.81, p 0.00028; post
hoc Tukey HSD tests, control vs Hoxb8-Cre/GLT1flox/flox, p 0.95;
control vs GLAST//GLT1flox/flox, p  0.0027; control vs
GLAST//GLT1-cKO, p 0.0020; Hoxb8-Cre/GLT1flox/flox vs
GLAST//GLT1flox/flox, p  0.0015; Hoxb8-Cre/GLT1flox/flox
vs GLAST//GLT1-cKO, p 0.0012; GLAST//GLT1flox/flox
vs GLAST//GLT1-cKO, p 0.99]). There was no compensa-
tory upregulation of other glutamate transporters (GLAST and
EAAC1) in Hoxb8-Cre/GLT1flox/flox, GLAST//GLT1flox/flox,
and GLAST//GLT1-cKO mice (Fig. 1E,F [Fig. 1F: one-way
ANOVA, F(3,8) 0.095, p 0.96]). Thus, we succeeded in gen-
erating spinal cord-specific astroglial glutamate transporters
knock-out mice.
Impaired motor function andmotor neuron loss in
GLAST//GLT1-cKO mice
The most appropriate controls for GLAST//GLT1-cKO mice
are GLAST//GLT1flox/flox mice. However, there was no differ-
ence in the expression levels of GLAST and GLT1 between
GLAST//GLT1 flox/flox and GLAST/ mice. In addition,
GLAST/ mice did not show apparent survival differences or
any obvious abnormalities in basic motor and neurological func-
tion compared with wild-typemice (Watase et al., 1998; Karlsson
et al., 2009; Aida et al., 2015). Thus, we used GLT1flox/flox mice as
controls instead of GLAST//GLT1flox/flox mice in this study.
GLAST//GLT1-cKO mice had lower body weights than did
the controls starting at 7weeks of age [Fig. 1G (two-way repeated-
measures ANOVA for genotype  age interaction: F(4,116) 
41.40, p  1.8E-21; post hoc unpaired two-tailed t tests: P5W,
t(29) 0.41, p 0.69; P6W, t(29) 1.10, p 0.28; P7W, t(29)
3.89, p 0.00054; P8W, t(29) 5.42, p 7.8E-06; P9W, t(29)
8.46, p 2.6E-09)]. They displayed an impaired hindlimb reflex
by 7 weeks of age, after which they progressively lost grip strength
and became fully paralyzed in the hindlimbs by 8 weeks of age
[Fig. 1H, I (Fig. 1H: two-way repeated-measures ANOVA for ge-
notype age interaction, F(4,116) 62.03, p 6.2E-28; post hoc
Figure 6. Nuclear export inhibitor KPT-350 transiently ameliorates motor deficits, motor neuron loss in GLAST//GLT1-cKO mice. A, KPNB1 immunofluorescence of motor neurons in the
lumbar ventral horn from control and GLAST//GLT1-cKO mice at 7 weeks of age. Sections were triple labeled with anti-KPNB1 (green), DAPI (blue), and anti-ChAT (white). Scale bar, 10m.
B, RanBP-1 immunofluorescence ofmotor neurons in the lumbar ventral horn fromcontrol andGLAST//GLT1-cKOmice at 7weeks of age. Sectionswere triple labeledwith anti-RanBP-1 (green),
DAPI (blue), and anti-ChAT (white). Scale bar, 10m. C, CAS immunofluorescence of motor neurons in the lumbar ventral horn from control and GLAST//GLT1-cKO mice at 7 weeks of age.
Sections were triple labeled with anti-CAS (red), DAPI (blue), and anti-ChAT (white). Arrowheads indicate the reduction or absence of nuclear CAS immunoreactivity in GLAST//GLT1-cKOmice.
Scale bar, 10m. D, KPT-350 treatment delayed motor deficits in the hanging wire test (n 10 for vehicle-treated and n 9 for KPT-350-treated GLAST//GLT1-cKOmice). *p 0.05 ( post
hoc unpaired two-tailed t test at corresponding time point after two-way repeated-measures ANOVA). E, Amelioration of hindlimb paralysis in GLAST//GLT1-cKOmice after KPT-350 treatment.
Arrow indicates the fully paralyzed hindlimb of the vehicle-treated GLAST//GLT1-cKO mice. Arrowhead indicates the hindlimb upon which the KPT-350-treated GLAST//GLT1-cKO mice
could stand. F, ChAT immunofluorescence of the lumbar ventral horn from vehicle-treated and KPT-350-treated GLAST//GLT1-cKOmice at 7weeks of age. Scale bar, 100m.G, Quantification
of ChAT-positive motor neurons at 7 weeks of age (n 7 for vehicle-treated and n 5 for KPT-350-treated GLAST//GLT1-cKO mice). ***p 0.001 (unpaired two-tailed t test). H, Nup153
immunofluorescence of lumbar ventral horns from vehicle-treated and KPT-350-treated GLAST//GLT1-cKO mice at 7 weeks of age. Sections were triple labeled with anti-Nup153 (magenta),
DAPI (blue), and Neurotrace (fluorescent Nissl stain, white). Rectangles in the middle panel are enlarged in the right panel. Scale bars: left, 20 m; right, 5 m. (I) Quantitative analysis of
Nup153-immunostained sections. The percentage of Nup153-negative large ventral horn neurons is not changed in GLAST//GLT1-cKOmice treatedwith KPT-350 (n 3 for each groups). n.s.,
Not significant (unpaired two-tailed t test). All data are expressed as the mean SEM.
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unpaired two-tailed t tests, P5W, t(29) 0.98, p 0.33; P6W, t(29)
1.14, p 0.26; P7W, t(29) 3.79, p 0.0007; P8W, t(29) 13.75,
p  3.1E-14; P9W, t(29)  13.97, p  2.1E-14; Fig. 1I: two-way
repeated-measures ANOVA for genotype  age interaction,
F(4,116) 37.49, p 4.2E-20; post hoc unpaired two-tailed t tests,
P5W, t(29) 1.01, p 0.32; P6W, t(29) 0.16, p 0.88; P7W, t(29)
1.89, p 0.072; P8W, t(29) 8.03, p 7.4E-09; P9W, t(29) 8.80,
p 1.1E-09)]. Thereafter, they had shortened life spans [Fig. 1J
(log rank test, p 0.000016)]. There was no significant difference
in progression of motor deficits and survival rate betweenmale and
female GLAST//GLT1-cKO mice (data not shown). In some
GLAST//GLT1-cKOmice, spasmsof upper and lower limbmus-
cles were observed, which were followed by an extremely rapid dis-
ease progression withmice dying within 3–4 d.
Because GLAST//GLT1-cKO mice showed progressive
motor deficits that resulted in hindlimb paralysis, we next exam-
ined whether GLT1 and GLAST deletion caused motor neuron
loss and gliosis. ChAT immunolabeling showed motor neuron
loss in lumbar ventral horn of GLAST//GLT1-cKO mice be-
ginning at 7 weeks of age with a peak at 8 weeks of age [Fig. 2A,B
(Fig. 2B: unpaired two-tailed t tests, P5W, t(7)  0.98, p  0.36;
P6W, t(6) 0.38, p 0.72; P7W, t(5) 1.78, p 0.14; P8W, t(4)
3.70, p 0.021; P9W, t(7) 4.75, p 0.0021; P20W, t(5) 10.85,
p  0.00012). In contrast, there was no change in the number
of NeuN-positive neurons in the superficial dorsal horn in
GLAST//GLT1-cKO mice [Fig. 2C,D (Fig. 2D: unpaired two-
tailed t tests, P5W, t(4)  0.26, p  0.81; P7W, t(6)  0.73, p 
0.49; P9W, t(5)  0.20, p  0.85; P20W, t(4)  0.06, p  0.96)].
Furthermore, enhanced immunoreactivity forGFAP, amarker of
astroglia, and CD68, a marker of activated microglia, was de-
tected in the ventral horn of the spinal cord of GLAST//GLT1-
cKO mice beginning at 7 weeks of age (symptomatic stage; Fig.
Figure 7. Effects of long-term treatment with perampanel, SNJ-1945, and KPT-350 in GLAST//GLT1-cKO mice. A, Perampanel treatment for 6 weeks delayed motor deficits in the hanging
wire test (n 20 for vehicle-treated and n 16 for perampanel-treated GLAST//GLT1-cKO mice). B, Percentage survival of vehicle-treated (n 20) and perampanel-treated (n 16)
GLAST//GLT1-cKOmice calculatedusing theKaplan–Meiermethod ( p0.076, log rank test). n.s., Not significant.C, ChAT immunofluorescence of the lumbar ventral horn fromvehicle-treated
and perampanel-treated GLAST//GLT1-cKO mice at 12 weeks of age. D, Quantification of ChAT-positive motor neurons at 12 weeks of age (n  4 for vehicle-treated and n  6 for
perampanel-treated GLAST//GLT1-cKOmice). E, SNJ-1945 treatment for 6 weeks delayedmotor deficits in the hanging wire test (n 18 for vehicle-treated and n 16 for SNJ-1945-treated
GLAST//GLT1-cKOmice).F, Percentage survival of vehicle-treated (n18) and SNJ-1945-treated (n16)GLAST//GLT1-cKOmice calculatedusing theKaplan–Meiermethod ( p0.026,
log rank test). *p 0.05. G, ChAT immunofluorescence of the lumbar ventral horn from vehicle-treated and perampanel-treated GLAST//GLT1-cKOmice at 12 weeks of age.H, Quantification
of ChAT-positive motor neurons at 12 weeks of age (n 4 for vehicle-treated and n 6 for SNJ-1945-treated GLAST//GLT1-cKO mice). I, Amelioration of motor dysfunction by KPT-350
treatment was observed at 7 weeks of age but not at later (n 19 for vehicle-treated and n 14 for KPT-350-treated GLAST//GLT1-cKOmice). J, Percentage survival of vehicle-treated (n
19) and KPT-350-treated (n 14) GLAST//GLT1-cKOmice calculated using the Kaplan-Meiermethod ( p 0.86, logrank test). n.s., Not significant.K, ChAT immunofluorescence of the lumbar
ventral horn fromvehicle-treatedandKPT-350-treatedGLAST//GLT1-cKOmiceat 12weeksof age.L, Quantificationof ChAT-positivemotorneuronsat 12weeksof age (n4 for vehicle-treated
and n 6 for KPT-350-treated GLAST//GLT1-cKOmice). Scale bars: C, G, K, 100m. A, E, I, *p 0.05, **p 0.01, ***p 0.001 ( post hoc unpaired two-tailed t test at corresponding time
point after two-way repeated-measuresANOVA).D,H, L, *p0.05. n.s., Not significant (unpaired two-tailed t test). Redbroken lines represent the first day of administration. All data are expressed
as the mean SEM.
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2E,G). Quantification indicated a significant increase of GFAP-
positive and CD68-positive cells in the ventral horn of the spinal
cord of GLAST//GLT1-cKOmice beginning at 8 weeks of age
[Fig. 2F,H [Fig. 2F: unpaired two-tailed t tests, P5W, t(4) 0.33,
p 0.76; P6W, t(4) 0.86, p 0.44; P7W, t(6) 0.55, p 0.60;
P8W, t(4)  8.39, p  0.0011; P9W, t(4)  19.97, p  3.7E-05;
P20W, t(4)  4.51, p  0.011; Fig. 2H: P5W, t(4)  1.09, p 
0.34; P6W, t(4) 1.34, p 0.25; P7W, t(6) 1.39, p 0.21; P8W,
t(4) 2.91, p 0.044; P9W, t(4) 4.10, p 0.015; P20W, t(4)
4.00, p 0.016)].
Together, these results suggest that the dysfunction of astro-
glial glutamate transporters, GLT1 and GLAST, induced spinal
motor neuron loss, resulting in severe hindlimb paralysis in vivo.
Involvement of AMPA receptors overactivation in spinal
motor neuron loss of GLAST//GLT1-cKOmice
Excess extracellular glutamate due to the dysfunction of astroglial
glutamate transporters induces neuronal death via overactivation
of ionotropic glutamate receptors. In particular, previous works
have demonstrated the contribution of AMPA receptors (Coura-
tier et al., 1993; Carriedo et al., 1996; Kwak and Weiss, 2006;
Hideyama et al., 2010; Akamatsu et al., 2016; Yamashita et al.,
2017b) and/or NMDA receptors to spinal motor neuron deaths
(Mitchell et al., 2010; Sasabe et al., 2007, 2012). To determine the
subtype of ionotropic glutamate receptor that is involved in mo-
tor neuron death in GLAST//GLT1-cKO mice, we examined
the effects of AMPA andNMDA receptor antagonists.We treated
GLAST//GLT1-cKO mice with perampanel (Hanada et al.,
2011), an AMPA receptor antagonist that is used as an antiepi-
leptic drug. Akamatsu et al. (2016) reported that perampanel (20
mg/kg) prevented the progression of the ALS phenotype in the
AR2 mice, in which an RNA editing enzyme adenosine deami-
nase acting on RNA 2 (ADAR2) is conditionally knocked out in
the motor neurons. Thus, GLAST//GLT1-cKO mice were
treated daily with perampanel (20 mg/kg, orally) starting at 6
weeks of age. Perampanel administration for 7 d preventedmotor
deficits and motor neuron loss in GLAST//GLT1-cKO mice
[Fig. 3A–D (Fig. 3A: two-way repeated-measures ANOVA for
drug  time interaction, F(1,30)  4.76, p  0.037; post hoc un-
paired two-tailed t test, P7W, t(30)  2.48, p  0.019; Fig. 3D:
one-way ANOVA, F(2,9)  18.93, p  0.0006; post hoc Tukey’s
HSD tests, control vs vehicle-treated GLAST//GLT1-cKO,
p  0.00048; control vs perampanel-treated GLAST//GLT1-
cKO, p  0.045; vehicle-treated vs perampanel-treated GLAST//
GLT1-cKO, p 0.0104)]. Next, to investigate the role of NMDA
receptors in spinal motor neuron death in GLAST//GLT1-
cKOmice, we treated GLAST//GLT1-cKOmice withmeman-
tine (Lipton, 2006), an NMDA receptor antagonist. Wang and
Zhang (2005) reported that treating SOD1 (G93A) mice with
memantine (10 mg/kg) significantly delayed the disease progres-
sion and prolonged survival. We administered memantine (10
mg/kg, i.p., twice per day) every day for 7 d to GLAST//GLT1-
cKOmice at 6 weeks of age. Memantine treatment for 7 d had no
effect on motor function decline and motor neuron loss [Fig.
3E–G (Fig. 3E: two-way repeated-measures ANOVA for drug
time interaction, F(1,14) 1.71, p 0.21; Fig. 3G: unpaired two-
tailed t test, t(5) 1.25, p 0.27)]. Furthermore,we examined the
effect of another NMDA receptor antagonist, MK-801. Gill et al.
(1987) demonstrated that systemic administration of MK-801
(3 mg/kg) completely protected ischemia-induced hippocampal
damage in the gerbil. We administered MK-801 (3 mg/kg, i.p.)
every day for 14 d to GLAST//GLT1-cKO mice at 6 weeks of
age. MK-801 treatment for 14 d could not prevent the progres-
sion of motor deficits andmotor neuron loss [Fig. 3H–J (Fig. 3H:
two-way repeated-measures ANOVA for drug  time interac-
tion, F(2,18)  0.02, p  0.98; Fig. 3J: unpaired two-tailed t test,
t(4) 0.83, p 0.46)].
These results suggest that overstimulation of AMPA recep-
tors, but not NMDA receptors, induces motor neuron loss and
severe motor deficits in this new in vivomodel of chronic spinal
cord excitotoxicity.
Calpain-dependent degradation of nuclear pore complex
proteins in GLAST//GLT1-cKOmice
We next examined the mechanisms by which the overactivation
of AMPA receptors results in motor neuron death. An electron
microscopic analysis revealed nuclear irregularities in spinal mo-
tor neurons of GLAST//GLT1-cKO mice (Fig. 4A), which re-
sembles the pathologies of ALS and Parkinson’s disease patients
(Kinoshita et al., 2009; Liu et al., 2012). The nuclear irregularity
seen by electronmicroscopy was accentuated by lamin B1 immu-
nostaining. In the large ventral hornneurons of controlmicewith
a nuclear diameter of10 m, lamin B1 immunoreactivity was
distributed predominantly as smooth nuclear contours (Fig. 4B).
In contrast, the percentage of large ventral horn neurons exhib-
iting nuclear contour irregularity such as flayed and discontinu-
ousmorphology is significantly higher inGLAST//GLT1-cKO
mice as early as 5weeks of age (presymptomatic stage; Fig. 4B,C).
The large ventral horn neurons with an irregular nuclear contour
became the most common type of large ventral horn neurons in
GLAST//GLT1-cKOmice from 7week of age to 9 weeks of age
[symptomatic stage; Fig. 4C (unpaired two-tailed t tests, P4W,
t(4)  0.33, p  0.76; P5W, t(5)  3.72, p  0.014; P6W, t(8) 
4.38, p 0.0024; P7W, t(7) 7.39, p 0.00015; P8W, t(4) 5.16,
p  0.0067; P9W, t(4)  6.60, p  0.0027)]. These observations
prompted an examination of nuclear pore complexes (NPCs)
that were embedded in the nuclear envelope in the large ventral
horn neurons of GLAST//GLT1-cKOmice. We examined the
immunohistochemical distribution of the major protein compo-
nent of NPCs, Nup153 (Fahrenkrog and Aebi, 2003; Kinoshita et
al., 2009; Freibaum et al., 2015). Whereas Nup153 immunoreac-
tivity was distributed predominantly along smooth nuclear con-
tours in controls, it was reduced in large ventral horn neurons of
GLAST//GLT1-cKO mice at 6 weeks of age [Fig. 4D,E (Fig.
4E: unpaired two-tailed t tests, P4W, t(4) 1.48, p 0.21; P5W,
t(5)  1.30, p  0.25; P6W, t(4)  3.27, p  0.031; P7W, t(5) 
10.68, p  0.00012)]. Double immunostaining of Nup153 and
ChAT revealed that the percentage of Nup 153-negative motor
neurons is significantly increased to the same extent as Nup 153-
negative large ventral horn neurons in GLAST//GLT1-cKO
mice at 7 weeks of age [Fig. 4F,G (Fig. 4G: unpaired two-tailed t
test, t(7) 5.12, p 0.0014)]. These results indicate the reduced
NPC expression was occurred in the spinal motor neurons of
GLAST//GLT1-cKO mice.
The loss of NPC protein immunolabeling on the nuclear en-
velope suggests NPC protein degradation. Recent studies showed
that nucleoporins were cleaved by Ca2-activated protease cal-
pain (Bano et al., 2010; Yamashita et al., 2017a). Consistent with
this, an in vitro assay (Sato et al., 2011) using mouse brain ho-
mogenates displayed that the amounts of detectable full-length
Nup62, Nup88, and Nup153 were decreased in a Ca2-depen-
dent manner, whereas SNJ-1945 (Oka et al., 2006), a calpain
inhibitor, reversed the loss of these proteins (Fig. 5A). However,
laminB1 was not a calpain substrate (Fig. 5A). In addition, we
observed that the cleavage of p35, which is well known as a cal-
pain substrate (Lee et al., 2000), was significantly enhanced in the
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spinal cords of GLAST//GLT1-cKO mice at 6 weeks of age
compared with the control mice [Fig. 5B,C (Fig. 5C: unpaired
two-tailed t tests, P5W, t(4) 0.97, p 0.39; P6W, t(5) 5.10, p
0.0038)]. These results suggest that calpain is hyperactivated in
the spinal cord of GLAST//GLT1-cKOmice. To confirm this,
we measured calpain activity of the spinal cords. An increase in
calpain activity in lumbar ventral hornwas observed inGLAST//
GLT1-cKO mice as early as 5 weeks of age [Fig. 5D (unpaired
two-tailed t tests, P4W, t(9) 0.28, p 0.79; P5W, t(9) 3.05, p
0.014; P6W, t(9)  2.90, p  0.018)]. Yamashita et al. (2012,
2017b) and Yamashita and Kwak (2014) have reported that TAR
DNA binding protein (TDP-43), one of the disease-related pro-
teins of ALS and FTD, was also cleaved by calpain (Akamatsu et
al., 2016). Thus, we assessed the immunohistochemical analysis
for TDP-43. Immunofluorescence for TDP-43 demonstrated
that TDP-43 localized exclusively to the nuclei in all of the spinal
motor neurons in control mice, whereas some spinal motor neu-
rons in GLAST//GLT1-cKO mice exhibited aberrant staining
patterns of TDP-43, such as mislocalization to the cytoplasm
(mislocalization), nuclear reduction without cytoplasmic immu-
noreactivity (reduction), and the absence from both the nucleus
and the cytoplasm (absence; Fig. 5E). Although the number of
motor neurons showing aberrant staining patterns of TDP-43
was very low, we detected such motor neurons in GLAST//
GLT1-cKO mice as early as 5 weeks of age [Fig. 5F (unpaired
two-tailed t tests, P5W, t(12) 3.32, p 0.0061; P6W, t(9) 2.84,
p  0.019; P7W, t(9)  3.94, p  0.0034; P9W, t(9)  2.53, p 
0.032)]. The percentage of motor neurons devoid of TDP-43
increased between 7 and 9 weeks of age when motor neuron loss
was prominent (Fig. 5F). Consistent with previous reports (Ya-
mashita et al., 2012, 2017b; Akamatsu et al., 2016), TDP-43 was
cleaved by calpain (Fig. 5G), suggesting that various immuno-
staining patterns of TDP-43 in motor neurons of GLAST//
GLT1-cKO mice may result from cleavage by calpain.
To verify whether calpain-mediated NPC degradation was
linked to motor deficits and neuronal death of GLAST//
GLT1-cKO mice, we examined the effects of a blood–brain
barrier-permeable calpain inhibitor, SNJ-1945, in GLAST//
GLT1-cKO mice. Imai et al. (2010) reported that SNJ-1945 (200
mg/kg) significantly prevented light-induced photoreceptor de-
generation in the mice. Thus, we treated mice daily with SNJ-
1945 (200 mg/kg, orally) starting at 6 weeks of age. One week of
SNJ-1945 treatment prevented the loss of grip strength of the
hindlimbs in GLAST//GLT1-cKO mice [Fig. 5H (two-way
repeated-measures ANOVA for drug time interaction, F(1,14) 
8.59, p 0.011; post hoc unpaired two-tailed t test, P7W, t(14)
2.93, p  0.011)]. Furthermore, SNJ-1945 delayed the loss of
spinal motor neurons and Nup153 immunoreactivity [Fig. 5I–L
(Fig. 5J: unpaired two-tailed t test, t(9) 3.30, p 0.0093; Fig. 5L:
unpaired two-tailed t test, t(6) 4.86, p 0.0028)]. In addition,
we also investigated a role for AMPA receptors in the degradation
of Nup153 in GLAST//GLT1-cKOmice. One week of peram-
panel treatment (20 mg/kg, orally) prevented the degradation of
Nup153 [Fig. 5M,N (Fig. 5N: unpaired two tailed t test, t(7) 
3.34, p  0.012)] as well as the death of spinal motor neurons
(Fig. 3C,D) in GLAST//GLT1-cKO mice.
Together, these findings suggest that the hyperactivation of
calpain due to the overactivation of AMPA receptors is involved
in the degradation of the major protein components of NPCs,
which is associatedwith excitotoxic spinalmotor neuron death in
GLAST//GLT1-cKO mice.
Effects of short-term treatment with the nuclear export
inhibitor KPT-350 in GLAST//GLT1-cKOmice
Nucleocytoplasmic transport has a crucial role in cell viability,
and the loss of nucleoporins has been reported to impair nuclear
import and export (Roth et al., 2003; Pemberton and Paschal,
2005; Bano et al., 2010; Nishimura et al., 2010;Makise et al., 2012;
Yamashita et al., 2017a). Because GLAST//GLT1-cKO mice
showed the reduction ofNup153 inmotor neurons, we examined
the changes in the subcellular localization of proteins involved in
nucleocytoplasmic trafficking. The spinal motor neurons in
GLAST//GLT1-cKOmice exhibited normal nuclear immuno-
reactivity for KPNB1, which is the member of karyopherin
protein family responsible for protein import, and normal cyto-
plasmic immunoreactivity for RanBP1, which regulates the as-
sembly and disassembly of karyopherin-cargo complex (Fig.
6A,B). In contrast, subcellular localization of CAS protein, known
as exportin-2, was different between controls and GLAST//
GLT1-cKOmice. Immunoreactivity for CAS was predominant in
the nucleus of motor neurons in control mice, whereas some
spinal motor neurons in GLAST//GLT1-cKO mice showed
reduced levels of CAS in the nucleus at 7 weeks of age (early
symptomatic stage, Fig. 6C). Although the number of CAS-
negativemotor neurons was low, the percentage of CAS-negative
motor neuronswas increased inGLAST//GLT1-cKOmice at 7
weeks of age [CAS ()/ChAT () cells (%): control, 2.3 1.3%;
GLAST//GLT1-cKO, 12.7 2.6%; unpaired two-tailed t test,
t(5)  3.21, p  0.024]. These results indicate that nucleocyto-
plasmic transport was slightly impaired in some motor neurons
in GLAST//GLT1-cKO mice.
To examine whether nucleocytoplasmic transport deficits are
involved in motor dysfunction and motor neuron loss in
GLAST//GLT1-cKOmice, we analyzed the effect of KPT-350,
a nuclear export inhibitor (Haines et al., 2015), because the in
vivo toxicity of all the other modifiers of nucleocytoplasmic
transport precluded their use. GLAST//GLT1-cKOmice were
treated every other day with KPT-350 (15 mg/kg, orally) starting
at 6 weeks of age. GLAST//GLT1-cKOmice treated with KPT-
350 delayed motor deficits in the hanging wire test, whereas
GLAST//GLT1-cKO mice treated with vehicle showed com-
plete hindlimb paralysis [Fig. 6D,E (Fig. 6D: two-way repeated-
measuresANOVA for drug time interaction,F(1,17) 7.98, p
0.012; post hoc unpaired two-tailed t test, P7W, t(17) 2.82, p
0.012)]. KPT-350 treatment also delayed motor neuron loss in
GLAST//GLT1-cKO mice [Fig. 6F,G (Fig. 6G: unpaired two-
tailed t test, t(10)  4.83, p  0.00069)]. However, the effects of
KPT-350 were transient, and long-term treatment of KPT-350
did not prevent motor neuron loss and motor deficits in GLAST//
GLT1-cKOmice (Fig. 7 I,K,L). Although KPT-350 delayed motor
neuron death andmotor deficits in GLAST//GLT1-cKOmice,
the degradation of Nup153 was not prevented [Fig. 6H, I (Fig. 6I:
unpaired two-tailed t test, t(4) 0.13, p 0.90)].
Together, these findings suggest that nucleocytoplasmic trans-
port deficits may partially contribute to excitotoxic spinal motor
neurondegeneration inGLAST//GLT1-cKOmice, butmay be
not a major cause of motor neuron loss in GLAST//GLT1-
cKO mice.
Effects of long-term treatment with perampanel, SNJ-1945
and KPT-350 in GLAST//GLT1-cKOmice
We next evaluated the efficacy of long-term treatment with
perampanel, SNJ-1945, and KPT-350 on the phenotypes of
GLAST//GLT1-cKO mice. GLAST//GLT1-cKO mice were
treated daily with perampanel (20 mg/kg, orally) or SNJ-1945
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(200 mg/kg, orally) for 42 d starting at 6 weeks of age. Since the
treatment of control mice with a 15mg/kg dose of KPT-350 three
times per week for 3 weeks causes serious weight loss, we orally
administered KPT-350 (7.5 mg/kg) three times per week from 6
to 12weeks of age.Drug-treated and vehicle-treated animalswere
monitored daily for survival and weekly for grip strength. The
results showed that motor function decline was delayed by the
administration of perampanel or SNJ-1945 [Fig. 7A,E (Fig. 7A:
two-way repeated-measures ANOVA for drug  time interac-
tion, F(6,204)  5.59, p  2.2E-05; post hoc unpaired two-tailed t
tests, P7W, t(34) 2.44, p 0.020; P8W, t(34) 3.18, p 0.0031;
P9W, t(34)  2.70, p  0.011; P10W, t(34)  4.28, p  0.00014;
P11W, t(34) 4.64, p 5.0E-05; P12W, t(34) 5.37, p 5.8E-06;
Fig. 7E: two-way repeated-measures ANOVA for drug  time
interaction, F(6,192)  7.16, p  6.6E-07; post hoc unpaired two-
tailed t tests, P7W, t(32)  3.79, p  0.00062; P8W, t(32)  2.63,
p 0.013; P9W, t(32) 2.86, p 0.0074; P10W, t(32) 3.64, p
0.00095; P11W, t(32)  3.88, p  0.000495; P12W, t(32)  4.12,
p  0.00025)]. In contrast, KPT-350 treatment delayed motor
deficits at 7 weeks of age but not later in GLAST//GLT1-cKO
mice [Fig. 7I (two-way repeated-measures ANOVA for drug 
time interaction, F(6,186)  8.85, p  1.7E-08; post hoc unpaired
two-tailed t test, P7W, t(31) 3.03, p 0.0049)]. SNJ-1945 treat-
ment prolonged survival in GLAST//GLT1-cKOmice [Fig. 7F
(log rank test, p  0.026)], whereas KPT-350 treatment had no
effect on survival [Fig. 7J (log rank test, p  0.86)]. Although
there is a tendency for survival rate to be higher in perampanel-
treated GLAST//GLT1-cKO mice, there is no significant
difference between perampanel-treated and vehicle-treated
GLAST//GLT1-cKOmice (Fig. 7B (log rank test, p 0.076)].
Consistent with these results, 6 weeks of treatment with peram-
panel or SNJ-1945 prevented motor neuron loss in GLAST//
GLT1-cKO mice at 12 weeks of age [Fig. 7C,D,G,H (unpaired
two-tailed t test: Fig. 7D: t(8)  2.93, p  0.019; Fig. 7H: t(8) 
3.21, p 0.013)]. On the other hand, the neuroprotective effect
of KPT-350 was observed at 7 weeks of age but not at 12 weeks of
age [Figs. 6F,G, 7K,L (Fig. 7L: unpaired two-tailed t test, t(8) 
0.01, p 0.98)]. These results indicate that both perampanel and
SNJ-1945 have continued robust protective effects, while the pro-
tective effects of KPT-350 in GLAST//GLT1-cKO mice are
transient. Thus, preventing NPC degradation by peramapanel or
SNJ-1945 has robust protective effects on motor neurons.
Discussion
In this study, we generated a new animal model of excitotoxicity:
a spinal cord-specific astroglial glutamate transporter (GLT1 and
GLAST) double-knock-out mouse. We further demonstrated
that GLAST//GLT1-cKO mice showed selective motor neu-
ron loss and severe hindlimb paralysis, which recapitulated the
symptom of motor neuron diseases such as ALS. These findings
suggest that combined loss of astroglial glutamate transporters
GLT1 and GLAST is required to induce motor neuron death
leading to paralysis in vivo.
Our results suggest a possible mechanism for spinal motor
neuron death that is induced by excitotoxicity (Fig. 8), which
includes the following: (1) dysfunction or reduction of astroglial
glutamate transporters, which increases extracellular glutamate;
(2) an increase in glutamate-induced AMPA receptor activation,
not NMDA receptor activation, thereby leading to an increase in
intracellular Ca2 levels; (3) calpain hyperactivation by Ca2
overload; (4) the degradation of NPCs by calpain; (5) the loss of
nuclear integrity or other unknown mechanisms; and (6) the
induction of motor neuron death (Fig. 8).
GLAST//GLT1-cKO mice exhibited nuclear membrane
abnormalities and calpain-mediated degradation of NPCs. An
increase in the percentage of motor neurons exhibiting nuclear
pathology preceded motor neuron death in GLAST//GLT1-cKO
mice, suggesting that nuclear pathology is an early pathological
event following calpain activation in GLAST//GLT1-cKO
mice. In addition, long-term treatment of perampanel and SNJ-
1945 has continued beneficial effects in motor neuron loss and
the degradation of Nup153. Consistent with this, a recent study
has demonstrated that activated calpain degraded NPCs via up-
regulation of Ca2-permeable AMPA receptors in motor neu-
rons of ADAR2 conditional knock-out (AR2)mice (Yamashita et
al., 2017a). Together, these results indicate that nuclear mem-
brane abnormalities and degradation ofNPCsmay be involved in
motor neuron death that is driven by AMPA receptor-mediated
excitotoxicity.
How do nuclear membrane abnormalities and degradation of
NPCs actually lead to motor neuron death? The nucleocytoplas-
mic transport through NPCs plays a crucial role in maintaining
cell viability and cellular functions (Pemberton and Paschal,
2005). Furthermore, previous studies have shown that nucleocy-
toplasmic transport deficits due to calpain-dependent degrada-
tion of the NPCs were observed in glutamate-treated cultured
Figure 8. Model of AMPA receptor-induced spinal motor neuron death. In spinal cord-
specific GLT1 and GLAST double-knock-out mice, the reduction of astroglial glutamate trans-
porters (GLAST and GLT1) induces spinal motor neuron death as follows: (1) an increase in
extracellular glutamate concentration; (2) an increase in glutamate-induced AMPA receptor
activation, thereby leading to an increase in intracellular Ca 2 levels; (3) the Ca 2 overload-
induced activation of calpain; (4) hyperactivated calpain degradation of NPCs; (5) impairment
of nuclear pore function may progress to nuclear “leakiness”; and (6) induces motor neuron
death. Glutamate-induced spinal motor neuron death can be reversed following long-term
treatment with the antiepileptic AMPA receptor antagonist perampanel and the calpain inhib-
itor SNJ-1945. AMPAR, AMPA receptor; NMDAR, NMDA receptor; Nup62, Nucleoporin 62;
Nup88, Nucleoporin 88; Nup153, Nucleoporin 153.
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neurons and AR2 mice (Bano et al., 2010; Yamashita et al.,
2017a). In this study, we showed that a selective inhibitor of
nuclear export KPT-350 delayed but did not prevent motor neu-
ron death in GLAST//GLT1-cKO mice. In addition, only a
small number of motor neurons showed the change in the sub-
cellular localization of CAS in GLAST//GLT1-cKO mice. To-
gether, the nucleocytoplasmic transport deficits may transiently
contribute tomotor neuron death, butmay not be amajor down-
stream pathway to cause motor neuron death following NPCs
degradation in GLAST//GLT1-cKOmice. Thus, further stud-
ies are required to reveal the contribution of nucleocytoplasmic
transport defects to motor neuron death and the downstream
mechanisms of the NPCs degradation in GLAST//GLT1-cKO
mice.
Although our study suggests that the combined loss of glial
glutamate transporters is required to recapitulate the ALS-like
symptoms such asmotor neuron death leading to paralysis, there
was no report showing a reduction of GLAST expression in ALS
patients. Thus, additional studies are required to evaluate the
clinical relevance of GLAST//GLT1-cKOmice to human ALS.
In this study, we demonstrated that motor neuron death was
partially recovered by the pharmacological blockade of AMPA
receptor and calpain activation, which could inhibit the degrada-
tion of Nup153. Therefore, our findings suggest that perampanel
and SNJ-1945 could be a novel therapeutic strategy for many
acute and chronic neurological diseases that involve AMPA
receptor-mediated excitotoxicity, such as ischemic or traumatic
injury and ALS.
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